Abstract 1748P
Background
Obesity has been recognised as one of the main risk factors for non- communicable diseases including cancer. WHO European report suggests that obesity affects 30% of children in Europe. Unhealthy diet is one of the most important determinants of childhood obesity, a condition that has become very prevalent in the south of Europe. Consumption of sugar-sweetened beverages (SSBs) influence childhood obesity and food advertisement is one of the strongest determinants of SSB consumption.
Methods
A multidisciplinary panel of clinicians from the South of Europe (Cyprus, Greece, Italy, Malta, Spain and Portugal) critically reviewed the available legislation and recommendations on SSB advertisements, in native language. The website of relevant national societies (Cardiovascular, Diabetic, Oncology, Paediatric and Stroke) was reviewed. Herein we present the recommendations from Oncology national societies.
Results
The countries in study have national legislations on SSB advertisements following EU directives with Spain having the most comprehensive regulatory framework. None of the oncology societies had recommendations on SSB consumption from children. The Spanish oncology society (SEOM) recognised obesity as risk factor for developing cancer and a close collaboration with the Spanish Association for the study of obesity is suggested. The Portuguese Society of Oncology (SPO) provides general guidance on the role of food and nutrition in cancer development. In Greece and Cyprus sporadic publications from the oncology society (HeSMO) on the preventive role of diet was noticed with no concrete guidance. Italian Oncology society (AIOM) has published on the role of nutritional support for cancer patients but the preventive role of healthy diet on childhood obesity is not available. European society of Medical Oncology links to IARC prevention strategies in the society website.
Conclusions
Recommendations on healthy diet to tackle childhood obesity, including SSB advertisement, from national medical societies in South Europe is fragmented. Oncology societies should join forces with other medical societies to increase awareness of childhood obesity and implement measures to address the phenomenon.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1890P - Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)
Presenter: Christopher Darr
Session: Poster session 23
1891P - Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma
Presenter: Renee Saliby
Session: Poster session 23
1892P - A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)
Presenter: Rana McKay
Session: Poster session 23
1895P - Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)
Presenter: Sara Elena Rebuzzi
Session: Poster session 23
1896P - Clinical management and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab+ipilimumab (N+I): A real-world study
Presenter: Tom Geldart
Session: Poster session 23
1897P - Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Presenter: Francesco Massari
Session: Poster session 23
1899P - Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab + nivolumab (ipi+nivo) vs. PD-1/L1 inhibitor (PDI) + tyrosine kinase inhibitor (TKI)
Presenter: Georges Gebrael
Session: Poster session 23
1900P - Role of cytoreductive nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the national cancer database (2004-2020)
Presenter: ALINA BASNET
Session: Poster session 23